patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_574177 | REC_0004501 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.5 | 58 | female | 0 | 34 | 2.6 | 1 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.958972+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827890 | REC_0004502 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 9.2 | 75 | female | 2 | 7 | 4.9 | 8 | sotorasib 960 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:57.959201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257297 | REC_0004503 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.2 | 59 | male | 1 | 12 | 4.5 | 6 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:57.959437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438958 | REC_0004504 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 19.1 | 73 | female | 2 | 11 | 5.5 | 5 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:57.959679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902079 | REC_0004505 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 15.5 | 73 | female | 1 | 16 | 8.2 | 2 | sotorasib 960 mg daily | 23.5 | true | MSS | 2026-03-15T05:35:57.959916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_521163 | REC_0004506 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 31 | 6.4 | 66 | female | 0 | 69 | 4.9 | 4 | pembrolizumab 200 mg q3w | 14.8 | true | MSS | 2026-03-15T05:35:57.960223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413027 | REC_0004507 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 15.4 | 66 | female | 1 | 12 | 6.5 | 0 | sotorasib 960 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:57.960481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686142 | REC_0004508 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 13.4 | 55 | female | 0 | 5 | 5.6 | 6 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:35:57.960748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801898 | REC_0004509 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 7.5 | 75 | female | 1 | 8 | 4.1 | 7 | osimertinib 80 mg daily | 7.6 | false | MSS | 2026-03-15T05:35:57.960992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152765 | REC_0004510 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 11.6 | 52 | female | 0 | 17 | 6.5 | 6 | osimertinib 80 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:57.961232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387098 | REC_0004511 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11 | 62 | male | 1 | 14 | 6.7 | 6 | osimertinib 80 mg daily | 7.3 | true | MSS | 2026-03-15T05:35:57.961487+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990563 | REC_0004512 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11 | 64 | female | 1 | 12 | 5.9 | 5 | entrectinib 600 mg daily | 9.7 | false | MSI-H | 2026-03-15T05:35:57.961881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436403 | REC_0004513 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.8 | 63 | female | 1 | 20 | 3.8 | 7 | alectinib 600 mg BID | 8.7 | true | MSI-H | 2026-03-15T05:35:57.962150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962248 | REC_0004514 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 2.9 | 75 | female | 3 | 44 | 6.2 | 9 | pembrolizumab 200 mg q3w | 10.1 | false | MSS | 2026-03-15T05:35:57.962388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859986 | REC_0004515 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12.5 | 55 | female | 0 | 22 | 6 | 4 | entrectinib 600 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:57.962638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355192 | REC_0004516 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 9 | 60 | female | 1 | 67 | 4.8 | 4 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:35:57.962878+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419402 | REC_0004517 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 17.1 | 61 | female | 1 | 17 | 7.7 | 3 | osimertinib 80 mg daily | 4.6 | true | MSS | 2026-03-15T05:35:57.963120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904839 | REC_0004518 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 8.3 | 63 | male | 0 | 14 | 6.7 | 5 | entrectinib 600 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.963356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974928 | REC_0004519 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 20 | 15 | 66 | female | 1 | 17 | 7.6 | 0 | alectinib 600 mg BID | 31.7 | true | MSS | 2026-03-15T05:35:57.963594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_226068 | REC_0004520 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 11.5 | 66 | female | 1 | 12 | 5.7 | 4 | osimertinib 80 mg daily | 5.2 | false | MSS | 2026-03-15T05:35:57.963834+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917186 | REC_0004521 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 8.3 | 63 | female | 1 | 22 | 6.3 | 2 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:57.964146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473845 | REC_0004522 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 9.3 | 64 | male | 1 | 18 | 4.8 | 2 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.964400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511429 | REC_0004523 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 13.1 | 66 | male | 0 | 13 | 6.2 | 3 | sotorasib 960 mg daily | 13.2 | false | MSI-H | 2026-03-15T05:35:57.964640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853847 | REC_0004524 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.9 | 72 | female | 2 | 16 | 4.4 | 5 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.964874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358760 | REC_0004525 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.7 | 69 | female | 0 | 14 | 5.5 | 3 | entrectinib 600 mg daily | 19.7 | false | MSI-H | 2026-03-15T05:35:57.965203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_607441 | REC_0004526 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 6.5 | 88 | female | 1 | 11 | 4.5 | 1 | entrectinib 600 mg daily | 22.1 | true | MSS | 2026-03-15T05:35:57.965437+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254620 | REC_0004527 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.3 | 58 | male | 0 | 71 | 6.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:57.965676+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270819 | REC_0004528 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 11.7 | 70 | female | 1 | 0 | 5.2 | 4 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:57.965908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737157 | REC_0004529 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 14.2 | 62 | male | 1 | 4 | 6.2 | 6 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:57.966150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409418 | REC_0004530 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 8.3 | 77 | female | 1 | 14 | 5.6 | 6 | entrectinib 600 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.966377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446430 | REC_0004531 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.8 | 78 | female | 1 | 11 | 2.6 | 1 | alectinib 600 mg BID | 8.8 | true | MSS | 2026-03-15T05:35:57.966605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350396 | REC_0004532 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.8 | 72 | female | 2 | 13 | 5.9 | 5 | sotorasib 960 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:35:57.966841+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234237 | REC_0004533 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.1 | 65 | male | 0 | 67 | 4.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:35:57.967074+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915039 | REC_0004534 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.9 | 64 | male | 1 | 12 | 3.6 | 3 | entrectinib 600 mg daily | 7.1 | true | MSS | 2026-03-15T05:35:57.967311+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648751 | REC_0004535 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 12.8 | 77 | female | 2 | 18 | 7.3 | 6 | osimertinib 80 mg daily | 13.8 | false | MSS | 2026-03-15T05:35:57.967545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473871 | REC_0004536 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 8.1 | 68 | male | 0 | 15 | 6.3 | 4 | pembrolizumab 200 mg q3w | 17.5 | true | MSS | 2026-03-15T05:35:57.967781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107328 | REC_0004537 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 7.9 | 57 | male | 1 | 10 | 6.3 | 6 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:57.968012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212925 | REC_0004538 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.1 | 74 | male | 3 | 20 | 3.4 | 7 | sotorasib 960 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:57.968355+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580560 | REC_0004539 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 12.1 | 57 | male | 1 | 11 | 4.4 | 1 | osimertinib 80 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:57.968601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884412 | REC_0004540 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.8 | 68 | female | 2 | 14 | 5.1 | 5 | osimertinib 80 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:57.968843+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977385 | REC_0004541 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.5 | 71 | female | 3 | 14 | 8.8 | 1 | pembrolizumab 200 mg q3w | 28.3 | false | MSS | 2026-03-15T05:35:57.969073+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729158 | REC_0004542 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.7 | 59 | female | 1 | 59 | 6.3 | 5 | pembrolizumab 200 mg q3w | 15.6 | false | MSS | 2026-03-15T05:35:57.969309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488669 | REC_0004543 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 8.2 | 66 | male | 0 | 29 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.7 | true | MSS | 2026-03-15T05:35:57.969542+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622797 | REC_0004544 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.5 | 73 | female | 1 | 32 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 14.6 | false | MSS | 2026-03-15T05:35:57.969772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776251 | REC_0004545 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.5 | 79 | male | 2 | 22 | 5.6 | 2 | sotorasib 960 mg daily | 27.5 | false | MSI-H | 2026-03-15T05:35:57.970009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791639 | REC_0004546 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 22 | 12.6 | 63 | male | 0 | 26 | 9 | 0 | pembrolizumab 200 mg q3w | 32 | true | MSS | 2026-03-15T05:35:57.970245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224408 | REC_0004547 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 7.5 | 70 | female | 1 | 13 | 5.7 | 2 | osimertinib 80 mg daily | 23.5 | false | MSS | 2026-03-15T05:35:57.970475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239070 | REC_0004548 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 5.7 | 74 | female | 1 | 13 | 6 | 1 | pembrolizumab 200 mg q3w | 24.6 | false | MSS | 2026-03-15T05:35:57.970708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747808 | REC_0004549 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 8.7 | 69 | female | 1 | 10 | 4.8 | 6 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.970936+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771633 | REC_0004550 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 9.2 | 70 | male | 2 | 19 | 5.7 | 6 | entrectinib 600 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.971167+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824248 | REC_0004551 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 14.2 | 58 | male | 1 | 18 | 6.4 | 2 | sotorasib 960 mg daily | 26.2 | false | MSI-H | 2026-03-15T05:35:57.971457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603435 | REC_0004552 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 14.6 | 64 | male | 1 | 10 | 4.8 | 2 | alectinib 600 mg BID | 15.2 | true | MSI-H | 2026-03-15T05:35:57.971701+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785052 | REC_0004553 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 26 | 3.5 | 72 | female | 2 | 28 | 4.8 | 0 | pembrolizumab 200 mg q3w | 33.2 | true | MSS | 2026-03-15T05:35:57.971939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963921 | REC_0004554 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 10.2 | 55 | male | 0 | 14 | 2.6 | 2 | alectinib 600 mg BID | 23.2 | true | MSI-H | 2026-03-15T05:35:57.972231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144835 | REC_0004555 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.7 | 68 | female | 1 | 50 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:57.972471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_749210 | REC_0004556 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 11.8 | 68 | female | 1 | 24 | 6.2 | 3 | osimertinib 80 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:57.972713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423049 | REC_0004557 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.9 | 61 | male | 0 | 8 | 7.4 | 4 | pembrolizumab 200 mg q3w | 15.1 | false | MSS | 2026-03-15T05:35:57.972951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_829013 | REC_0004558 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.7 | 66 | male | 0 | 20 | 6.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.1 | false | MSS | 2026-03-15T05:35:57.973184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375457 | REC_0004559 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 5.3 | 66 | female | 1 | 15 | 6.3 | 3 | osimertinib 80 mg daily | 17.8 | false | MSS | 2026-03-15T05:35:57.973412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_299508 | REC_0004560 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.3 | 65 | female | 0 | 63 | 6.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.8 | false | MSS | 2026-03-15T05:35:57.973644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267335 | REC_0004561 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 8.6 | 57 | male | 0 | 10 | 5.9 | 1 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:57.973879+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686870 | REC_0004562 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 8.8 | 63 | female | 0 | 9 | 5 | 1 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:57.974110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_446341 | REC_0004563 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.8 | 74 | female | 1 | 7 | 5.3 | 2 | sotorasib 960 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:57.974338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985223 | REC_0004564 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 10.1 | 64 | male | 1 | 16 | 5.7 | 1 | alectinib 600 mg BID | 20.4 | false | MSS | 2026-03-15T05:35:57.974627+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644481 | REC_0004565 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 8.4 | 70 | female | 2 | 19 | 7.5 | 1 | alectinib 600 mg BID | 21 | true | MSS | 2026-03-15T05:35:57.974866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128218 | REC_0004566 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 13 | 60 | male | 0 | 0 | 4.8 | 4 | osimertinib 80 mg daily | 5.3 | false | MSS | 2026-03-15T05:35:57.975101+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458067 | REC_0004567 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 34 | 5.6 | 80 | female | 1 | 6 | 7.7 | 7 | pembrolizumab 200 mg q3w | 13.8 | false | MSS | 2026-03-15T05:35:57.975329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831805 | REC_0004568 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 6.8 | 76 | female | 0 | 23 | 4.7 | 1 | osimertinib 80 mg daily | 29.3 | true | MSS | 2026-03-15T05:35:57.975557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186634 | REC_0004569 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 8.5 | 86 | female | 1 | 6 | 6.6 | 3 | osimertinib 80 mg daily | 13 | true | MSS | 2026-03-15T05:35:57.975784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114960 | REC_0004570 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 15.1 | 63 | female | 0 | 12 | 6.7 | 6 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:57.976018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140960 | REC_0004571 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.5 | 64 | male | 0 | 49 | 7.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:35:57.976459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376673 | REC_0004572 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 16.2 | 60 | male | 1 | 9 | 4.2 | 6 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:57.976724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462392 | REC_0004573 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 7.4 | 64 | male | 1 | 15 | 5.9 | 5 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:57.976962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838924 | REC_0004574 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.2 | 64 | male | 0 | 32 | 5.4 | 6 | pembrolizumab 200 mg q3w | 9.7 | true | MSS | 2026-03-15T05:35:57.977194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772804 | REC_0004575 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 10.8 | 57 | female | 1 | 4 | 6.8 | 2 | sotorasib 960 mg daily | 35.3 | true | MSI-H | 2026-03-15T05:35:57.977431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354893 | REC_0004576 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 17.4 | 68 | female | 0 | 15 | 5 | 1 | pembrolizumab 200 mg q3w | 16.9 | true | MSI-H | 2026-03-15T05:35:57.977664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320654 | REC_0004577 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 13 | 62 | female | 0 | 32 | 5.4 | 5 | pembrolizumab 200 mg q3w | 12.8 | true | MSI-H | 2026-03-15T05:35:57.977980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561233 | REC_0004578 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 16.8 | 85 | male | 2 | 14 | 6 | 2 | entrectinib 600 mg daily | 18 | true | MSS | 2026-03-15T05:35:57.978218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_427086 | REC_0004579 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 25 | 12.5 | 77 | female | 2 | 12 | 5.2 | 0 | osimertinib 80 mg daily | 36.7 | false | MSI-H | 2026-03-15T05:35:57.978452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741796 | REC_0004580 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 12.1 | 65 | male | 0 | 4 | 3.7 | 6 | alectinib 600 mg BID | 11 | false | MSI-H | 2026-03-15T05:35:57.978689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736086 | REC_0004581 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 12.8 | 63 | male | 0 | 14 | 4 | 2 | osimertinib 80 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:35:57.978923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823897 | REC_0004582 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 12 | 67 | male | 0 | 17 | 4.7 | 6 | osimertinib 80 mg daily | 15.9 | true | MSI-H | 2026-03-15T05:35:57.979157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178691 | REC_0004583 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 9.4 | 61 | female | 0 | 12 | 6.7 | 2 | alectinib 600 mg BID | 15.4 | false | MSS | 2026-03-15T05:35:57.979389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_189507 | REC_0004584 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 6.2 | 61 | female | 1 | 15 | 4.7 | 4 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.979628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513506 | REC_0004585 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 11.6 | 68 | male | 0 | 7 | 4.6 | 2 | entrectinib 600 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:57.979874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244388 | REC_0004586 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 15.3 | 74 | female | 2 | 29 | 5.2 | 6 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:57.980191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218491 | REC_0004587 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 17 | 9 | 56 | male | 0 | 7 | 5.2 | 4 | pembrolizumab 200 mg q3w | 15.3 | true | MSS | 2026-03-15T05:35:57.980448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388580 | REC_0004588 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 14.9 | 86 | female | 0 | 4 | 5.5 | 6 | entrectinib 600 mg daily | 6.9 | false | MSI-H | 2026-03-15T05:35:57.980696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839704 | REC_0004589 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 16.8 | 65 | male | 0 | 11 | 4.7 | 5 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:57.980946+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_938712 | REC_0004590 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 13.3 | 62 | male | 1 | 18 | 7.6 | 6 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:57.981285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501298 | REC_0004591 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 33 | 11.5 | 61 | male | 0 | 22 | 4.3 | 2 | entrectinib 600 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:57.981531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_634788 | REC_0004592 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.4 | 64 | female | 1 | 17 | 7 | 4 | osimertinib 80 mg daily | 7.2 | true | MSI-H | 2026-03-15T05:35:57.981780+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_117532 | REC_0004593 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 16.5 | 61 | female | 1 | 24 | 4 | 2 | osimertinib 80 mg daily | 22 | false | MSS | 2026-03-15T05:35:57.982033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922421 | REC_0004594 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 35 | 14.3 | 67 | female | 0 | 20 | 5.3 | 5 | entrectinib 600 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:57.982287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786154 | REC_0004595 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.6 | 77 | male | 2 | 12 | 4.4 | 1 | entrectinib 600 mg daily | 21.4 | false | MSS | 2026-03-15T05:35:57.982545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106546 | REC_0004596 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 9.8 | 74 | female | 1 | 23 | 6.6 | 1 | pembrolizumab 200 mg q3w | 20.9 | false | MSS | 2026-03-15T05:35:57.982782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893913 | REC_0004597 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.8 | 72 | male | 1 | 46 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.6 | true | MSS | 2026-03-15T05:35:57.983021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136421 | REC_0004598 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 20.2 | 75 | female | 2 | 16 | 6.4 | 6 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:35:57.983260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216380 | REC_0004599 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 10.3 | 49 | male | 0 | 18 | 4.5 | 1 | osimertinib 80 mg daily | 19.5 | true | MSS | 2026-03-15T05:35:57.983497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165569 | REC_0004600 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.6 | 72 | female | 0 | 11 | 5.2 | 3 | sotorasib 960 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:57.983734+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.